Noscapine-13C, d3

Noscapine-13C, d3 is a 13C- labeled and deuterated labeled Noscapine[1]. Noscapine ((S, R) -Noscapine) is an orally active phthalideisoquinoline alkaloid with potent antitussive. Noscapine exerts its antitussive effects by activating sigma opioid receptors and is a non-competitive Bradykinin inhibitor. Noscapine disrupts microtubule dynamics, induces mitotic arrest and apoptosis. Noscapine possesses anticancer, neuroprotective, anti-inflammatory activities, and can cross the blood-brain barrier[2][3][4][5][6].

Product Specifications

CAS Number

[1217680-57-3]

UNSPSC

12352005

Hazard Statement

H302-H315-H319-H335

Target

Apoptosis; Isotope-Labeled Compounds; Opioid Receptor

Type

Isotope-Labeled Compounds

Related Pathways

Apoptosis; GPCR/G Protein; Neuronal Signaling; Others

Applications

Cancer-programmed cell death

Field of Research

Cancer

Smiles

COC1=C(OCO2)C2=CC3=C1[C@@]([C@]4([H])C5=CC=C(OC)C(OC)=C5C(O4)=O)([H])N(CC3)[13C]([2H])([2H])[2H]

Molecular Formula

C21 13CH20D3NO7

Molecular Weight

417.43

Precautions

P261-P264-P270-P271-P280-P302+P352-P304+P340-P305+P351+P338-P330-P362+P364-P403+P233-P405-P501

References & Citations

[1] Jaren W Landen, et al. Noscapine Crosses the Blood-Brain Barrier and Inhibits Glioblastoma Growth. Clin Cancer Res. 2004 Aug 1;10 (15) :5187-201.|[2]Yunfan Yang, et al. CYLD Regulates Noscapine Activity in Acute Lymphoblastic Leukemia via a Microtubule-Dependent Mechanism. Theranostics. 2015 Mar 2;5 (7) :656-66.|[3]Vartika Tomar, et al. Noscapine and Its Analogs as Chemotherapeutic Agent: Current Updates. Curr Top Med Chem. 2017;17 (2) :174-188.|[4]Bianca Lokhorst, et al. Interaction of OTC Drug Noscapine and Acenocoumarol and Phenprocoumon. Br J Clin Pharmacol. 2019 May;85 (5) :1041-1043.|[5]S A Ebrahimi, et al. Interaction of Noscapine With the Bradykinin Mediation of the Cough Response. Acta Physiol Hung. 2003;90 (2) :147-55.|[6]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53 (2) :211-216.